These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31420811)

  • 1. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
    Presa M; Pérez-Ruiz F; Oyagüez I
    Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
    Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
    Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
    Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
    Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
    Perez-Ruiz F; Díaz-Torné C; Carcedo D
    J Med Econ; 2016 Jun; 19(6):604-10. PubMed ID: 26855041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective.
    Klein RW; Kabadi S; Cinfio FN; Bly CA; Taylor DC; Szymanski KA
    J Comp Eff Res; 2018 Aug; 7(8):807-816. PubMed ID: 29792516
    [No Abstract]   [Full Text] [Related]  

  • 8. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of febuxostat in chronic gout.
    Beard SM; von Scheele BG; Nuki G; Pearson IV
    Eur J Health Econ; 2014 Jun; 15(5):453-63. PubMed ID: 23719971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
    Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
    J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of allopurinol and febuxostat for the management of gout.
    Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM
    Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
    Gandhi PK; Gentry WM; Ma Q; Bottorff MB
    J Manag Care Spec Pharm; 2015 Feb; 21(2):165-75. PubMed ID: 25615006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
    J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat in the management of gout: a cost-effectiveness analysis.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study.
    Alghamdi YS; Soliman MM; Nassan MA
    BMC Pharmacol Toxicol; 2020 Feb; 21(1):10. PubMed ID: 32041665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.